Kurt Rote

Kurt Rote has held various positions in the biotechnology and industrial sectors over the past 16 years. In 2020, they became Principal at Longbow Immunotherapy. Prior to that, they were a Board Member and Founder at KaliVir Immunotherapeutics (2019), Founder, Board Member and CEO at Western Oncolytics Ltd. (2012), Head of Product Development and Marketing at BiognoSYS AG (2011), Strategy and Business Development, Sr. Analyst at Holcim US Inc. (2006), and Supervisor/Project Coordinator at McMaster-Carr (2004).

Kurt Rote obtained an MBA from IMD in 2010, focusing on Business Administration. Prior to that, they completed a B.S.E. in Biomedical Engineering from Duke University between 2001 and 2004.